Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes

Usama Gergis(Thomas Jefferson University Hospital), Koen van Besien(University Hospitals of Cleveland), Gail J. Roboz(Cornell University), Emeline Masson Frenet(New York Blood Center), Cynthia Romeo(New York Blood Center), Adrienne A. Phillips(Palmetto Hematology Oncology), Michael S. Samuel(Cancer Research UK Scotland Institute), Joseph M. Scandura(Cornell University), Tsiporah B. Shore(Cornell University), Pinkal Desai(NewYork–Presbyterian Hospital), Ellen K. Ritchie(Cornell University), Ludy Dobrila(New York Blood Center), Andromachi Scaradavou(NewYork–Presbyterian Hospital), Jingmei Hsu(Cancer Research Institute), Sang‐Min Lee(Seoul National University), Sebastian Mayer(Mount Sinai Hospital), Jeffrey Ball(Cornell University), Anthony Blanco(NewYork–Presbyterian Hospital), Maria S. Albano(New York Blood Center)
Transplantation and Cellular Therapy
November 8, 2018
10.1016/j.bbmt.2018.11.002
Cited by 4

Related Papers

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k